Loading organizations...
§ Venture Capital · Chicago, IL, USA
Investment adviser firm managing hedge funds for institutional investors, focused on healthcare, life sciences.
Apothecary Capital LLC operates as a specialized investment advisory firm dedicated to the healthcare sector. The firm provides capital and strategic guidance to emerging and established companies within the healthcare landscape, leveraging a deep understanding of biotechnology, pharmaceuticals, and medical technology. Its approach involves identifying and nurturing innovative solutions aimed at advancing patient care and industry efficiency.
The firm was founded in 2003 by Alan M. Sebulsky, a veteran of financial services with a focused expertise in healthcare. Prior to establishing Apothecary Capital, Sebulsky held significant roles at institutions such as Lincoln Capital Management Co. and Lehman Brothers Asset Management LLC, where he honed his insights into the unique investment opportunities and challenges within the healthcare industry, leading to the creation of his specialized firm.
Apothecary Capital strategically partners with promising healthcare companies, acting as a crucial financial and advisory partner for their growth initiatives. The firm's long-term vision is centered on fostering advancements across the healthcare ecosystem, supporting enterprises that develop impactful technologies and therapies. It aims to contribute to a future where healthcare innovation translates into tangible improvements for patients and the broader medical community.
BBT Capital Management/Apothecary Capital has 1 tracked investment across 1 company. The latest tracked deal is $37.0M Series D in Kythera Biopharmaceuticals in September 2011.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2011 | Kythera Biopharmaceuticals | $37.0M Series D | — | ARCH Venture Partners, Venrock, Altitude Life Science Ventures, Foley Ventures, Invus Financial Advisors, Jafco Ventures, Latham & Watkins, Partner Fund Management, Prospect Venture Partners, Versant Ventures |